Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA

CAR-T Digest - August 2020

25 June 2025: Huadong Medicine’s FGFR2b target ADC innovative drug HDM2020 China IND was approved by the NMPA

Zhongmei Huadong, a subsidiary of Huadong Pharmaceutical, received NMPA approval to initiate clinical trials of HDM2020 for injection for advanced solid tumors
HDM2020 is a novel ADC targeting FGFR2b, designed to deliver cytotoxic payloads specifically to tumor cells expressing this receptor
Preclinical studies showed HDM2020 has strong anti-tumor activity in FGFR2b-positive gastric cancer and squamous non-small cell lung cancer models, with favorable safety and druggability profiles
The NMPA accepted the clinical trial application in April 2025 and has now officially approved it, marking a critical milestone in HDM2020’s development
Huadong Pharmaceutical is strengthening its ADC oncology pipeline and global R&D ecosystem, aiming to develop differentiated ADCs and improve treatment options for cancer patients worldwide